ライフサイエンスコーパス: gadolinium

1 odamine, and imaging mass cytometry (IMC) of gadolinium.

2 omplex pressure-temperature phase diagram of gadolinium.

3 a health threat due to toxic effects of free gadolinium.

4 which is linked with an MRI contrast agent, gadolinium-1,4,7,10-tetraazacyclododecane-1,4,7-triaceta

5 (n = 3) underwent intra-arterial infusion of gadolinium 160 ((160)Gd)-labeled anti-human leukocyte an

6 studies evaluating intracranial retention of gadolinium after gadoxetic acid administration were at h

7 rt-circulating nanocarrier with MR-sensitive gadolinium and a long-circulating nanocarrier with fluor

8 Co-registered gadolinium and dysprosium concentration maps were genera

9 st Dooku1 as well as other Piezo1 inhibitors gadolinium and ruthenium red, and not mimicked by 2e.

10 terial administration of thrombin mixed with gadolinium and visualized the occlusion with real-time M

11 the exchange interactions between interlayer gadolinium atoms across IAEs, inducing the ferromagnetis

12 Gadolinium based contrast agents (GBCAs) have been linke

13 after administration of an elastin-specific gadolinium-based and a macrophage-specific iron-oxide-ba

14 Gadolinium-based chelates are a mainstay of contrast age

15 to serve as safe and improved alternative to gadolinium-based chelates.

16 d with fluids with varying concentrations of gadolinium-based contrast agent (0, 0.4, 0.8, 1.2, 1.6,

17 BackgroundThe safety of gadolinium-based contrast agent (GBCA) exposure during p

18 clusionThis study identified higher rates of gadolinium-based contrast agent (GBCA) exposure during t

19 ckground Gadolinium retention after repeated gadolinium-based contrast agent (GBCA) exposure has been

20 st five serial injections of the macrocyclic gadolinium-based contrast agent (GBCA) gadoterate meglum

21 the variation in MRF T(1) measurements post gadolinium-based contrast agent (GBCA) injection and the

22 with a prior hypersensitivity reaction to a gadolinium-based contrast agent (GBCA) often had breakth

23 American College of Radiology as a group III gadolinium-based contrast agent (GBCA), which indicates

24 mically stable and more sensitively detected gadolinium-based contrast agent (GBCA).

25 Purpose To measure the relationship between gadolinium-based contrast agent administration and irreg

26 Gadolinium-based contrast agent administration changed a

27 Conclusion At 3.0 T, use of a gadolinium-based contrast agent at follow-up MRI did not

28 , provide an overview of recent successes in gadolinium-based contrast agent development and assess t

29 ibrosis were reported, only seven were after gadolinium-based contrast agent exposure after 2008, ind

30 ergone multiple studies with the macrocyclic gadolinium-based contrast agent gadoterate meglumine.

31 Food and Drug Administration (FDA)-approved gadolinium-based contrast agent, gadopentetate dimeglumi

32 radiation, nephrotoxic contrast material, or gadolinium-based contrast agent.(C) RSNA, 2020.

33 Gadolinium-based contrast agents (GBCAs) are frequently

34 Gadolinium-based contrast agents (GBCAs) are used to pro

35 Background Despite the wide use of gadolinium-based contrast agents (GBCAs) for enhanced MR

36 reactions occur following administration of gadolinium-based contrast agents (GBCAs) for MRI examina

37 c systemic fibrosis (NSF) affects the use of gadolinium-based contrast agents (GBCAs) in MRI, there c

38 rnography with intrathecal administration of gadolinium-based contrast agents (GBCAs) is limited by a

39 ore than 20 serial injections of macrocyclic gadolinium-based contrast agents (GBCAs) on the signal i

40 s (NSF) after exposure to newer versus older gadolinium-based contrast agents (GBCAs) remains unclear

41 Background Hypersensitivity reactions to gadolinium-based contrast agents (GBCAs) that occur desp

42 ying the transport of hepatobiliary-specific gadolinium-based contrast agents (GBCAs) within the live

43 least 1 year after administration of linear gadolinium-based contrast agents (GBCAs), in line with p

44 tions, resulting in high cumulative doses of gadolinium-based contrast agents (GBCAs).

45 ear period after multiple administrations of gadolinium-based contrast agents (GBCAs).

46 immediate allergic events between classes of gadolinium-based contrast agents (GBCAs).

47 een reported in patients undergoing MRI with gadolinium-based contrast agents (GBCAs).

48 Gadolinium-based contrast agents are implicated in sever

49 ile to American College of Radiology group 2 gadolinium-based contrast agents for hypersensitivity re

50 opean Commission's regulations of the use of gadolinium-based contrast agents have required that the

51 Gadolinium-based contrast agents improved diagnostic per

52 Gadolinium-based contrast agents were not approved in th

53 nclusion The administration of two different gadolinium-based contrast agents, gadoxetate and gadoter

54 onance (MR) images after exposure to various gadolinium-based contrast agents.

55 ge in signal intensity varies with different gadolinium-based contrast agents.

56 mediators of the adverse effects induced by gadolinium-based contrast agents.

57 nemia, but it can serve as an alternative to gadolinium-based contrast agents.

58 ral orders of magnitude higher than those of gadolinium-based contrast agents.

59 Background Administration of a gadolinium-based contrast material is widely considered

60 Cardiac MRI was performed without and with gadolinium-based contrast material.

61 to administration of intravenous iodine- and gadolinium-based contrast material.

62 designated group II or group III intravenous gadolinium-based contrast media (GBCM).

63 weighted imaging after interstitial pedal of gadolinium-based contrast medium under local anesthesia.

64 e design, synthesis, and properties of a new gadolinium-based copper-responsive magnetic resonance im

65 cationic (iodine-based CA4+) and non-ionic (gadolinium-based gadoteridol) agents.

66 flammatory activity) and an elastin-specific gadolinium-based probe (0.2 mmol/kg, surrogate marker fo

67 were administered a type 1 collagen-targeted gadolinium-based probe (surrogate marker for extracellul

68 the volume transfer constant (K(trans)) for gadolinium between blood plasma and tissue extravascular

69 y nanosystem (TP-Gd/miRNA-ColIV) composed of gadolinium-chelated tannic acid (TA), low-toxic cationic

70 Gadolinium chelates are widely used in cardiovascular ma

71 Gadolinium chelating lipids were used to visualize the f

72 Macrophage depletion by gadolinium chloride pretreatment abrogated disease devel

73 Retained gadolinium colocalized with parenchymal iron.

74 ought to enhance the relaxivity of trivalent gadolinium complexes without sacrificing their stability

75 change coupling constant, J(Gd-rad), for the gadolinium compounds in this series to be tuned over a r

76 layed the strongest increase in both CNR and gadolinium concentration (p < 0.05).

77 rtifact was produced only with a 0.4 mmol/mL gadolinium concentration and when the tubing was either

78 lar space (v(e)), and initial area under the gadolinium concentration curve (IAUGC).

79 e neocortex (anterior cingulate cortex: mean gadolinium concentration, 0.28 ug . g(-1) +/- 0.04 [stan

80 > .05) to retention in the allocortex (mean gadolinium concentration, 0.33 ug . g(-1) +/- 0.04 in pi

81 e DCE-MRI series, and maps of area-under-the-gadolinium-concentration-curve-at-90 s (AUC(90s)) and th

82 he saline group (P > .42) and the cerebellar gadolinium concentrations decreased between weeks 5 and

83 Results The mean total gadolinium concentrations for gadodiamide and gadoterido

84 After 1 year, mean gadolinium concentrations in the cerebellum were 3.38 nm

85 gents (GBCAs), in line with persistent brain gadolinium concentrations with no elimination after the

86 be used to calculate the concentration of a gadolinium-containing contrast agent in a region of inte

87 ied to the characterization of an ultrasmall gadolinium-containing nanoparticle used as a theranostic

88 sing a long circulating blood-pool liposomal gadolinium contrast agent that does not penetrate the pl

89 Gadolinium contrast agents used in MRI are distributed w

90 that are associated with a "garland ring" of gadolinium contrast enhancement.

91 CE-MRI) can be used to model the movement of gadolinium contrast into the brain, expressed as the inf

92 ide nanoparticle, provides an alternative to gadolinium contrast material for MR angiography for safe

93 In 77% of patients, gadolinium contrast resolved by 60 days post-HCT.

94 Gadolinium contrast sequences were routinely implemented

95 effect-induced deformations in the brain on Gadolinium-contrast (Gd-C) T1w-MRI, and their impact on

96 This is even more pronounced in gadolinium, curium's lanthanide analogue, owing to the c

97 rately quantifies myocardial infarction than gadolinium delayed-enhancement MRI (DEMRI).

98 Gadolinium deposition has raised safety concerns, but it

99 inear agents, laser ablation ICP-MS revealed gadolinium depositions in the cerebellar nuclei.

100 ive laser ablation ICP-MS analysis showed no gadolinium depositions.

101 y for quantification and characterization of gadolinium deposits.

102 is known that the bone tissue can serve as a gadolinium depot, but so far only bulk measurements were

103 magnitude of J(Gd-rad) for the corresponding gadolinium derivatives that provides insight into the el

104 The distribution of gadolinium displays a specific accumulation pattern.

105 oral ring enhancement, which corresponded to gadolinium distribution detected with IMC.

106 lumine (three doses over 4 weeks; cumulative gadolinium dose, 7.2 mmol per kilogram of body weight; n

107 ical damages, delayed cortical and medullary Gadolinium elimination (perfusion), and reduced ATP leve

108 ubstrate spatial complexity analysis of late gadolinium enhanced cardiac magnetic resonance images ma

109 dels were constructed from a set of 699 late gadolinium enhanced cardiac magnetic resonance images or

110 ial complexity of grayscale patterns on late gadolinium enhanced cardiac magnetic resonance images to

111 without prior history of VAs underwent late gadolinium enhanced cardiac magnetic resonance images.

112 Features were derived from pre-PVI late gadolinium enhanced magnetic resonance images and from r

113 fibrosis distribution were derived from late gadolinium enhanced magnetic resonance imaging of 6 AF p

114 accurately predict, using only pre-PVI late gadolinium enhanced magnetic resonance imaging scans as

115 who underwent PVI and had preprocedural late gadolinium enhanced magnetic resonance imaging.

116 nt presentation, so comparison was made with gadolinium-enhanced brain MRI performed approximately 9

117 nt presentation, so comparison was made with gadolinium-enhanced brain MRI performed approximately 9

118 n CV and myocardial fibrosis density on late gadolinium-enhanced cardiac magnetic resonance imaging (

119 rule out a suspected thrombus, he underwent gadolinium-enhanced cardiac magnetic resonance imaging,

120 The presence of gadolinium-enhanced lesions during follow-up was also as

121 ind, randomized, two-period crossover study, gadolinium-enhanced MRI and phase-resolved functional lu

122 Using gadolinium-enhanced T1-weighted MRI, we determined that

123 ctive study, 156 pretreatment GBM MR images (gadolinium-enhanced T1-weighted, T2-weighted, and fluid-

124 permanent pacemaker and LVEF >35% with late gadolinium enhancement >5.7%, had high annualized event

125 1.8%) than those with both ischemia and late gadolinium enhancement (12.0%; P<0.001).

126 jection fraction (73% versus 68%), more late gadolinium enhancement (85% versus 15%), and a lower str

127 SP and were strongly associated with LV late gadolinium enhancement (90%), even in cases of acute myo

128 rization, electric markers of scar, and late gadolinium enhancement (all P<0.001).

129 Patients with late gadolinium enhancement (LGE) and low lateral MAPSE had s

130 the association between local CV versus late gadolinium enhancement (LGE) and myocardial wall thickne

131 Patients with no ischemia or late gadolinium enhancement (LGE) by CMR, observed in 1,583 p

132 Late gadolinium enhancement (LGE) cardiac magnetic resonance

133 r VT, can be noninvasively defined with late gadolinium enhancement (LGE) cardiovascular magnetic res

134 Late gadolinium enhancement (LGE) cardiovascular magnetic res

135 Late gadolinium enhancement (LGE) cardiovascular magnetic res

136 D by assessing myocardial perfusion and late gadolinium enhancement (LGE) imaging.

137 Areas of late gadolinium enhancement (LGE) in each image were assigned

138 Late gadolinium enhancement (LGE) is an important prognostic

139 Currently, late gadolinium enhancement (LGE) scans provide the only noni

140 Background Cardiac MRI late gadolinium enhancement (LGE) scar volume is an important

141 Left ventricular hypertrophy (LVH) and late gadolinium enhancement (LGE) were independent predictors

142 on the association of left atrial (LA) late gadolinium enhancement (LGE) with atrial voltage in pati

143 rt-axis slice of native T1 map, T2 map, late gadolinium enhancement (LGE), and automated extracellula

144 le) underwent DT-CMR in diastole, cine, late gadolinium enhancement (LGE), and extracellular volume (

145 ntal wall thickening percent, segmental late Gadolinium enhancement (LGE), and extracellular volume f

146 o detecting myocardial fibrosis through late gadolinium enhancement (LGE), extracellular volume fract

147 of reactive interstitial fibrosis, and late gadolinium enhancement (LGE), representing replacement f

148 ow native T1 (sphingolipid storage) and late gadolinium enhancement (LGE, scar).

149 elaxation times, ECV, myocardial edema, late gadolinium enhancement [LGE], and myocardial strain) par

150 ascular magnetic resonance imaging with late gadolinium enhancement and a 24-hour Holter.

151 sed with ALVC, defined as a LV isolated late gadolinium enhancement and fibro-fatty replacement at ca

152 Across all FD, late gadolinium enhancement and low native T1 were independen

153 ed disease controls increased T2 in the late gadolinium enhancement area (57+/-6 versus 60+/-7 ms; P=

154 A total of 72 patients (72%) showed late gadolinium enhancement at baseline with 57 (57%) having

155 There was no change in volume of late gadolinium enhancement at treatment.

156 ognostic value of inducible ischemia or late gadolinium enhancement by CMR.

157 ngs of left ventricular hypertrophy and late gadolinium enhancement can be used to identify patients

158 ostic value of the peri-infarct zone on late gadolinium enhancement cardiac magnetic resonance in isc

159 opathy and drug-refractory VT underwent late gadolinium enhancement cardiac MRI (CMR), (123)I-metaiod

160 ipients, myocardial fibrosis is seen on late gadolinium enhancement cardiovascular magnetic resonance

161 etermine whether myocardial fibrosis on late gadolinium enhancement cardiovascular magnetic resonance

162 UMI was defined as the presence of late gadolinium enhancement consistent with MI in the absence

163 5.2% ( P=0.0001) with prevalence of any late gadolinium enhancement dropping to 48%.

164 Patients without ischemia or late gadolinium enhancement experienced a lower annual event

165 Global late gadolinium enhancement extent dropped from 8.5+/-9.2% of

166 s underwent CMR including cine imaging, late gadolinium enhancement imaging (LGE) (replacement fibros

167 Preoperative CMR showed late gadolinium enhancement in 70% of the patients, whereas E

168 le for electrocardiographic imaging and late gadolinium enhancement in early diagnosis and noninvasiv

169 cardiac magnetic resonance imaging with late gadolinium enhancement in phenotyping the left ventricul

170 erwent CMR at 3.0 T including cine, and late gadolinium enhancement in subjects >45 years.

171 Cardiac magnetic resonance showed LV late gadolinium enhancement in the LV lateral and posterior b

172 Gadolinium enhancement indicates blood-brain barrier (BB

173 with LFLG-AS have higher ECV, iECV, and late gadolinium enhancement mass compared with high-gradient

174 Late gadolinium enhancement mass was also similar in patients

175 LV late gadolinium enhancement occurred with normal LV systolic

176 at baseline evaluation, the presence of late gadolinium enhancement on cardiac magnetic resonance ima

177 Nineteen percent had late gadolinium enhancement on cardiac magnetic resonance.

178 jection fraction (LVEF) >35% with >5.7% late gadolinium enhancement on cardiovascular magnetic resona

179 Only 1 patient presented with late gadolinium enhancement on cardiovascular magnetic resona

180 The optimal cutoff for the extent of late gadolinium enhancement predictive of the composite end p

181 and fibro-fatty replacement in areas of late gadolinium enhancement presence.

182 Indexed late gadolinium enhancement significantly decreased in G-CSF

183 native T1 mapping, with no evidence of late gadolinium enhancement suggestive of replacement fibrosi

184 LV late gadolinium enhancement was present in a primarily subepi

185 -Meier analysis, inducible ischemia and late gadolinium enhancement were significantly associated wit

186 e represents sphingolipid accumulation; late gadolinium enhancement with high T2 and troponin elevati

187 T1, T2, global longitudinal strain, and late gadolinium enhancement) and biomarkers (high-sensitive t

188 mal ventricular function (4/5, 80% with late gadolinium enhancement).

189 presence of a CMR diagnosis, extent of late gadolinium enhancement, and left and right ventricular e

190 and function, infarct size assessed by late gadolinium enhancement, and myocardial strain.

191 rformed, followed by CMR (cine imaging, late gadolinium enhancement, and T2-weighted imaging and T1 m

192 etic resonance (CMR) to assess LVEF and late gadolinium enhancement, indicative of ventricular fibros

193 rier compromise was suggested by parenchymal gadolinium enhancement, leukocyte recruitment, and endot

194 Future studies should confirm whether late gadolinium enhancement-cardiac magnetic resonance assess

195 Multivariable analysis adjusted for late gadolinium enhancement.

196 ted after adjusting for the presence of late gadolinium enhancement.

197 line and 12 months, inclusive of T2 and late gadolinium enhancement.

198 e reported in 2 females with low T1 and late gadolinium enhancement.

199 T2, extracellular volume fraction, and late gadolinium enhancement.

200 y more specific than LVEF >35% with any late gadolinium enhancement.

201 xed ECV (iECV) to body surface area and late gadolinium enhancement.

202 f 6-month wall thickening compared with late gadolinium enhancement.

203 77.8% (14/18) of patients had focal late gadolinium enhancement.

204 nted with cerebral demyelinating lesions and gadolinium enhancement.

205 tures such as diastolic dysfunction and late gadolinium enhancement.

206 structural and functional adaptations (late gadolinium enhancement/abnormal innervation) with detail

207 ients had brainstem predominant perivascular gadolinium enhancing lesions on magnetic resonance imagi

208 scriminated from non-CLIPPERS by: homogenous gadolinium enhancing nodules <3 mm in diameter without r

209 t one relapse or a new/enlarging T2-FLAIR or gadolinium- enhancing lesion), and its interaction with

210 Baseline gadolinium-enhancing (beta = 1.32, P < 0.01) and spinal

211 formation of new/newly enlarging T2 lesions, gadolinium-enhancing (Gd+) T1 lesions, new T1 hypointens

212 Baseline gadolinium-enhancing (odds ratio 3.16, P < 0.01) and spi

213 ratentorial, infratentorial, spinal cord and gadolinium-enhancing lesion number, brain and spinal cor

214 e relapse within 24 months plus at least one gadolinium-enhancing lesion within 12 months before scre

215 24 months before screening plus at least one gadolinium-enhancing lesion within the 12 months before

216 l, IQR = 25.2-65.3) or both brain and spinal gadolinium-enhancing lesions (62.5pg/ml, IQR = 42.7-71.4

217 ] = 0.51, 95% CI = 0.36-0.72, p < 0.001) and gadolinium-enhancing lesions (HR = 0.38, 95% CI = 0.23-0

218 SS)) and radiological variables (presence of gadolinium-enhancing lesions and lesion count), and thei

219 The reason for MRI and gadolinium-enhancing lesions at baseline did not influen

220 had more relapses and a higher likelihood of gadolinium-enhancing lesions compared with patients with

221 The mean (+/-SD) total number of gadolinium-enhancing lesions during weeks 12 through 24

222 d point was the total (cumulative) number of gadolinium-enhancing lesions identified on T(1)-weighted

223 Time to new/enlarging T2-hyperintense and gadolinium-enhancing lesions on brain magnetic resonance

224 the likelihood (OR 2.53, P=0.0096) of having gadolinium-enhancing lesions on MRI.

225 ovement confirmed at 6 months, the number of gadolinium-enhancing lesions per T1-weighted magnetic re

226 The number of gadolinium-enhancing lesions per T1-weighted MRI scan, t

227 dering 1- and 3-year MRI variables, baseline gadolinium-enhancing lesions remained significant and ne

228 Baseline gadolinium-enhancing lesions was also associated with pe

229 matory disease activity, evidenced by new or gadolinium-enhancing MRI lesions.

230 adobenate dimeglumine washout since the last gadolinium exposure.

231 was to examine the renal safety of MRI with gadolinium following liver transplantation.

232 yclic GBCAs showed an ongoing elimination of gadolinium from the brain during the entire observation

233 ed on yttrium iron garnet (YIG) films coated gadolinium gallium garnet (GGG) substrate.

234 the untreatable condition recently linked to gadolinium (Gd) exposure during MRI with contrast.

235 is considered highly effective for removing gadolinium (Gd) from the body.

236 Gadolinium (Gd) has been detected in the brain, bone and

237 001, an Abeta-targeted liposomal macrocyclic gadolinium (Gd) imaging agent, for MRI of amyloid plaque

238 production from thermal neutron capture in a gadolinium (Gd) infused tumor as a result of secondary n

239 In GBCAs gadolinium (Gd) is present in a bound chelated form.

240 based on the presence or absence of visible gadolinium (Gd) leakage.

241 Gadolinium (Gd)-based contrast agents are extensively us

242 In this regard, several types of gadolinium (Gd)-based nanomaterials have been introduced

243 Herein, gadolinium (Gd)-rose bengal coordination polymer nanodot

244 y, are almost exclusively small, hydrophilic gadolinium(III) based chelates.

245 uvette containing a solution of paramagnetic gadolinium(III) chelate in a non-polar solvent, placed b

246 We used a dinuclear paramagnetic gadolinium(III) complex chelate that changes MR image co

247 Gadolinium(III) complexes have been widely utilised as m

248 Gadolinium(III) complexes have recently been demonstrate

249 stance to metal ion release, or by moving to gadolinium(III)-free alternatives.

250 xy-tryptamide-diethylenetriaminepentaacetate gadolinium imaging depicted parenchymal and intraventric

251 the magnetocaloric effect (MCE) observed in gadolinium in a magnetic field change of 0-1 Tesla.

252 iments in which for the first time we mapped gadolinium in bone biopsy from a male patient with idiop

253 l intensity (SI) changes and the presence of gadolinium in the rat brain during a 1-year period after

254 f GFP-expressing marrow had an abrogation of gadolinium-induced pathology and displayed less GFP-posi

255 score (10.5 vs 7.0 points, p = 0.01), higher gadolinium intensity score (2.0 vs 1.3 points, p = 0.007

256 Gadolinium is a rare-earth element, which is normally no

257 Purpose To determine whether and where gadolinium is retained in rat and human cerebral cortex.

258 A protocol should be proposed in which gadolinium is used in selected patients.

259 ABC transporter TM287/288, we show that two gadolinium-labeled nanobodies allow us to quantify, via

260 Gadolinium lacks suitable isotopes for nuclear imaging.

261 were used to assess differences in absolute gadolinium levels and percentage of injected dose, respe

262 porous silica nanoparticles (MSNs) producing gadolinium-loaded MSN (Gd-MSN).

263 a percentage of injected dose, the levels of gadolinium measured were comparable between different do

264 Brain MRI and gadolinium measurements were performed with inductively

265 as inhibited by either 2 mM calcium, or 5 uM gadolinium, mediated by hemichannels with a unitary cond

266 h materializes a breathing kagome lattice of Gadolinium moments.

267 We first loaded gadolinium onto the surface of mesoporous silica nanopar

268 nthesis of monodisperse nanohelices based on gadolinium oxide (Gd(2)O(3)).

269 In addition, we performed Gadolinium perfusion sequences.

270 Elemental brain maps (gadolinium, phosphorus, zinc, copper, iron) for rat and

271 The gadolinium probe did not affect the visualization of the

272 xy-tryptamide-diethylenetriaminepentaacetate gadolinium, referred to as MPO-Gd, and cross-linked iron

273 Background Gadolinium retention after repeated gadolinium-based con

274 Results All GBCAs resulted in significant gadolinium retention in central and peripheral nervous t

275 omplete information documenting intracranial gadolinium retention in patients administered gadoxetic

276 tate dimeglumine exposure is associated with gadolinium retention in specific regions, subregions, an

277 s spectrometry analysis was used to quantify gadolinium retention in the brain, spinal cord, and peri

278 exposure to a linear or macrocyclic GBCA on gadolinium retention in the central and peripheral nervo

279 However, gadolinium retention in the cerebral cortex has not been

280 quantitative T1 measurements might indicate gadolinium retention in the globus pallidus.

281 owed region-, subregion-, and layer-specific gadolinium retention in the neocortex (anterior cingulat

282 Each subject underwent one measurement of gadolinium retention in the tibia with x-ray fluorescenc

283 Gadolinium retention was detected in the cerebral cortex

284 sensitivity reactions, NSF, and intracranial gadolinium retention.

285 the mechanosensitive ion channel antagonists gadolinium, ruthenium red and D-GsMTx4.

286 -designed magnetic system in the presence of gadolinium salts, which allows the levitation of calcium

287 early differentiated the distributions, with gadolinium solely in the polyp and iodine in the lumen o

288 Gadoteridol comprised 100% of the gadolinium species found in rats treated with gadoterido

289 tion, chemical form and fate of the retained gadolinium species remain unknown.

290 ctroscopically distinguishable nitroxide and gadolinium spin labels and Double Electron-Electron Reso

291 that the yttrium-86 isotope can be used as a gadolinium surrogate.

292 ECV was calculated from pre- and post-gadolinium T1 measurements of blood and myocardium, and

293 ce of nanoparticles to facilitate loading of gadolinium to tumor spheroids and to localize at a site

294 Early gadolinium uptake because of myocardial hyperemia may be

295 ro-X-ray fluorescence spectroscopy (SR-XRF), gadolinium was detected in human cortical bone tissue.

296 In the hepatic artery, the concentration of gadolinium was much higher than iodine (8.5 +/- 3.9 mg/m

297 Conclusion Gadolinium was retained in the spinal cord and periphera

298 Conclusion Tissue deposition of gadolinium was two- to fourfold higher following adminis

299 tudies demonstrated that some tissues retain gadolinium, which might further pose a health threat due

300 nsitive discrimination and quantification of gadolinium within the arteries and iodine within the liv